Does HRT affect cholesterol levels?

HRT can change cholesterol levels, and per published clinical guidelines, for most women these changes shift in a heart-friendly direction. The specific effect depends mainly on whether estrogen is taken by mouth or through the skin.

How HRT Influences Cholesterol

According to current NAMS guidelines, estrogen generally improves the "good" parts of cholesterol and reduces some of the "risky" parts. The route of administration matters:

• Oral estrogen (pills): Per FDA-approved prescribing information, oral estrogen lowers LDL (the "bad" cholesterol), raises HDL (the "good" cholesterol), and may raise triglycerides slightly.
• Transdermal estrogen (patch, gel, spray): According to current NAMS guidelines, transdermal estrogen lowers LDL and keeps triglycerides more stable compared with pills.
• Progesterone (micronized or compounded): Per published clinical guidelines, micronized progesterone has a largely neutral effect on cholesterol for most women.

Women sometimes use compounded or individualized doses when standard formulations do not meet their clinical needs. Per published clinical guidelines, compounded preparations can influence cholesterol in a similar general pattern to standard products because the effect derives from the hormone itself. Compounded medications are not FDA-approved. They have not been reviewed by the FDA for safety, effectiveness, or quality. FDA-approved medications should be considered first when commercially available options meet patient needs.

Why These Changes Happen

According to the Endocrine Society, estrogen interacts with the liver, which is the body's main cholesterol-regulating organ. When estrogen reaches the liver in higher concentrations (as with oral pills), it prompts the liver to adjust cholesterol production more strongly. Skin-based estrogen delivers steadier hormone levels and avoids a large first-pass liver effect, so the resulting changes tend to be more modest.

LDL ("bad" cholesterol): Per FDA-approved prescribing information, LDL carries cholesterol into artery walls, and estrogen use is generally associated with a reduction in LDL levels.

HDL ("good" cholesterol): According to current NAMS guidelines, HDL carries cholesterol away from arteries for removal, and estrogen — particularly oral estrogen — is associated with increases in HDL levels.

Triglycerides: Per published clinical guidelines, high triglyceride levels can affect cardiovascular and metabolic risk. Oral estrogen may raise triglycerides modestly, while transdermal estrogen typically does not produce the same increase.

What This Means for Clinical Decision-Making

• If cholesterol is borderline or mildly elevated: According to current NAMS guidelines, HRT often shifts lipid numbers in a favorable direction when initiated around the time of menopause.
• If triglycerides are already elevated or metabolic concerns are present: Per published clinical guidelines, transdermal estrogen is typically the preferred option due to its more predictable triglyceride profile.
• If progesterone is used: Per the Endocrine Society, most progesterone formulations, including compounded micronized progesterone, have little clinically meaningful effect on cholesterol.

According to the WHI long-term follow-up data, lipid changes associated with HRT can contribute to cardiovascular outcomes, with the timing of initiation relative to menopause onset being an important factor. Periodic cholesterol monitoring — typically once a year — is generally recommended to assess individual response.

Whether HRT is appropriate depends on individual health factors. A prescriber should determine the best approach based on a patient's complete medical history, including lipid profile, cardiovascular risk factors, and personal treatment goals.